OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biotechnology company specializing in antibody discovery technologies, formed through the de-SPAC combination of Avista Public Acquisition Corp. II, a blank-check company sponsored by Avista Capital Partners, with the OmniAb business unit spun out of Ligand Pharmaceuticals. Avista Public Acquisition Corp. II completed its initial public offering in 2021. This Form 10-Q, filed in May 2022, reflects the company during the period ahead of its merger close, which was finalized in late 2022, transitioning OmniAb into a publicly traded life sciences issuer. The company provides proprietary transgenic animal platforms and antibody discovery services to biopharmaceutical partners. Sign up on SpacDesk for complete filing histories, deal timelines, and analytics on OmniAb and the broader SPAC market.